Q1 2026 was operationally a step forward on multiple fronts: new long-term data from NXTCL-T1D reinforced the durability of the treatment effect, FUJIFILM Biosciences commercially launched NextCell-Cord RUO after the period, and the company closed a SEK15m directed issue to prolong cash runway. The phase ll-readout after the summer remains the most critical event in the near-term.
LÄS MER
